FDA approves first targeted pancreatic cancer drug
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Revolution Medicines' treatment for advanced pancreatic cancer, the first drug to attack a genetic cause of the aggressive, highly lethal malignancy
- Revolution Medicines' drug delivered median overall survival of 13.2 months versus 6.7 months for standard chemotherapy when used as a second-line treatment in a practice-changing trial
- Trump administration plans to announce new drug-pricing agreements with several midsized biotechs on Monday, per Bloomberg News
- Participating biotechs would offer outpatient drug discounts to state Medicaid programs tied to foreign-country prices — though state participation is optional — in exchange for exemptions from Medicare pilot programs and potential tariff relief
Why it matters: Advanced pancreatic cancer patients gain the first treatment targeting a genetic driver of the disease, with trial data showing roughly double the median survival of standard chemo. The administration's voluntary model tests whether foreign-reference pricing can reach U.S. Medicaid patients while shielding participating companies from Medicare discount pilots and tariff exposure.
Ask SkimNews
